CTI BIOPHARMA CORP
DelistedCIK 891293fmd_1B60HC0BNDXKDP7YA8MVS997V1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2023, 55 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 35 | 60 | 16 | 57 | 25 | 26 | 3 | 0 | 0 | 54 |
| Cost of revenue | 0 | 1 | 2 | 1 | 0 | 1 | – | – | 0 | 4 |
| Gross profit | 35 | 59 | 14 | 56 | 25 | 25 | – | – | 0 | 50 |
| Research and development | 34 | 65 | 77 | 65 | 33 | 36 | 24 | 26 | 39 | 37 |
| Selling, general and administrative | 42 | 56 | 54 | 45 | 31 | 22 | 19 | 18 | 56 | 85 |
| Operating income | (42) | (86) | (117) | (49) | (40) | (33) | (41) | (48) | (95) | (80) |
| Interest expense | 1 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 2 | 13 |
| Other non-operating income (expense) | (2) | (8) | (4) | (4) | (1) | 4 | 1 | (5) | (3) | (13) |
| Income before taxes | (44) | (94) | (121) | (53) | (41) | (29) | (40) | (52) | (98) | (93) |
| Net income | (43) | (93) | (119) | (52) | (41) | (29) | (40) | (52) | (98) | (93) |
| Net income to common shareholders | (50) | (96) | (123) | (52) | (45) | (29) | (40) | (52) | (98) | (93) |